Navigation Links
Verenium Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Date:3/1/2011

s

Revenues for the periods ended December 31, 2010 and 2009 were as follows (in thousands): Three Months Ended December 31,Year Ended December 31,2010200920102009Revenues:Animal Health and Nutrition

$
8,051$
8,934$
32,588$
32,781Grain Processing

3,8342,72813,4399,744All other products

1,3812004,3241,431Total product

13,26611,86250,35143,956Collaborative and grant

3311,4941,7224,863Total revenues

$
3,597$
3,356$
52,073$
48,819Total revenues for the year ended December 31, 2010 increased 7% to $52.1 million from $48.8 million in the prior year, with product revenues representing 90% or more of total revenues in both periods. Product revenues for the year ended December 31, 2010 increased 15% to $50.4 million from $44.0 million in the prior year, primarily due to an increase in Phyzyme profit share from Danisco, as well as an increase in revenues from grain processing enzymes, Fuelzyme, Veretase, Deltazym GA L-E5 and Xylathin, which continued to gain traction in the grain ethanol markets, and Purifine enzyme for the soybean oil processing market. Product revenue from non-Phyzyme products as a percentage of total product revenue increased to 35% for the year ended December 31, 2010 compared to 25% in the prior year.

Product Gross Profit

Product gross profit for the year ended December 31, 2010 increased 16% to $18.6 million from $16.0 million in the prior year, primarily due to improved fixed cost leverage on higher revenue, partially offset by the impact of manufacturing constraints compared to the prior year, resulting from the challenges of satisfying increased demand for our products and expanded product mix.

Operating Expenses (excluding cost of product revenue)

Excluding cost of product revenues, total operating expenses related to continuing operations decreased to $33.9 million (including share-based compensation of $1
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Verenium Announces 2010 Business Update and Outlook for 2011
2. Verenium Announces Changes in Senior Management
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... VALHALLA, N.Y. , Jan. 14, 2014   Oligomerix, Inc. ... disease modifying therapeutics for Alzheimer,s disease (AD) and related ... headquarters to Valhalla, NY as ... additional laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... June 22, 2011 CardioFocus, Inc., developer of the ... atrial fibrillation (AF), announced today that its technology will ... upcoming European Heart Rhythm Association (EHRA) EUROPACE 2011 congress, ... EAS is a unique catheter ablation technology that incorporates ...
... SHENZHEN, China, June 22, 2011 /PRNewswire-Asia/ -- Winner Medical Group ... Company"), a leading manufacturer of medical dressings, medical disposables and ... today announced the Company,s management team will present at the ... to be held on June 27 and 28, 2011 at ...
Cached Medicine Technology:CardioFocus HeartLightâ„¢ Endoscopic Ablation System to be Featured at EHRA EUROPACE 2011 2CardioFocus HeartLightâ„¢ Endoscopic Ablation System to be Featured at EHRA EUROPACE 2011 3Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 2Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 3
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... By looking at ... structure and function, personality, life experiences and genetics, researchers can ... binge drinking within the next two years. Impulsivity, hopelessness, sensation-seeking ... events and a family history of drug use contribute to ... child had had a single drink at age 14 was ...
(Date:7/9/2014)... the world have been linked to an emerging ... the National Institute for Mathematical and Biological Synthesis ... contribute. , In a series of mathematical ... hemorrhage of internal organs in frogs, could cause ... they are exposed to the virus every few ...
(Date:7/9/2014)... of Allergy and Infectious Diseases (NIAID), part of ... early-stage clinical trial of CRS3123, an investigational oral ... ( C. difficile ) infection. CRS3123 (previously known ... C. difficile growth while sparing normal intestinal bacteria. ... to 30 healthy men and women ages 18 ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... is widespread among U.S. adolescents and young adults ages 14 ... the University at Buffalos Research Institute on Addictions (RIA). ... the first national survey of its kind show problem gambling ... (for example, gambling more than you intended or stealing money ...
... Vascular Insights LLC announced,today that it has received ... (FDA) to market its ClariVein(TM) infusion catheter for,infusion ... ClariVein(TM) is a percutaneous, 2 2/3 Fr (0.035") ... that enhances fluid dispersion in the,treatment area., ...
... 6 Epitomics, Inc. announced,today that its Hangzhou ... and production of its novel line of rabbit ... standard for quality management and ultimately the finest ... Dr. Guo-Liang Yu,President and CEO of Epitomics, Inc., ...
... Care Management: Making a ... Difference Today and Tomorrow, HARRISBURG, ... Medical Officer, will deliver the clinical keynote,address on Wednesday afternoon, ... the World of Care Management. Dr. Petrulis will,present Care Management: ...
... at dilated veins seen with cirrohosis but aren,t sensitive ... New noninvasive methods to detect esophageal bleeding in people ... Italian and American researchers. , About 25 percent of ... are extremely dilated veins commonly seen with cirrhosis. Variceal ...
... bowel movement, serious complications can follow, experts note , , ... have identified a marker that might predict which pregnant ... is essentially a baby,s first bowel movement, excreted in ... It is considered a sign of fetal distress. A ...
Cached Medicine News:Health News:Estimated 750,000 problem gamblers among America's youth 2Health News:Estimated 750,000 problem gamblers among America's youth 3Health News:Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies. 2Health News:KePRO's Chief Medical Officer to Deliver Clinical Keynote Address 2Health News:Noninvasive Procedures Show Promise for Esophageal Bleeding 2Health News:Doctors Discover Marker for Meconium Passage During Delivery 2
The most versatile 90 full field perimeter for static- and kinetic perimetry. It incorporates standard White-on-White and Blue-on-Yellow static perimetry. Octopus 101 covers all the needs in clinics ...
Automatic tangent screen with plane type central field tester. Static, quantitative perimetry....
... The Humphrey Matrix represents the ... Using frequency doubling technology, the Humphrey ... thorough visual field evaluation and assess ... enables you to provide complete long-term ...
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
Medicine Products: